---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-088236"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:25:20.393641+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics reports Q2 net income of $55.4M, on track for Phase 3 FSHD data by Oct 2024

## Summary
- Net income $55.4M vs net loss $23.8M in Q2 2023; revenue $80M from Sanofi upfront payment.
- Cash and securities $273.8M as of June 30, 2024; expected to fund operations into 2027.
- Phase 3 REACH trial (losmapimod for FSHD) topline data expected by end of October 2024; 260 patients enrolled.
- Collaboration with Sanofi for ex-U.S. losmapimod; $80M upfront received in Q2.
- Phase 1b pociredir (SCD) advancing; cohorts at 12 mg and 20 mg once daily planned.

## SEC filing metadata
- accession: 0000950170-24-088236
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000095017024088236/0000950170-24-088236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000095017024088236/fulc-20240731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-088236
- JSON: https://secwatch.observer/filing/0000950170-24-088236.json
- Plain text: https://secwatch.observer/filing/0000950170-24-088236.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.